S Sethi. Journal Club. The Internet Journal of Radiology. 2007 Volume 8 Number 1.
Article---Nephrogenic Systemic Fibrosis: Risk Factors and Incidence Estimation .
Nephrogenic systemic fibrosis (NSF) is a rare multisystemic fibrosing disorder that principally affects the skin but may affect other organs of patients with renal insufficiency. It is a newly recognized cutaneous fibrosing disorder marked by the acute onset of induration involving the upper and lower limbs in patients with acute or chronic renal failure. There is growing recognition of the association between the use of gadolinium-containing radiocontrast agents for magnetic resonance imaging and the serious dermal and systemic disease nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis (NFD/NSF). The pathogenesis of this entity remains unclear; however, recent observations suggest a likely mechanism for the initial dermal manifestations of this gadolinium toxicity
Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. [J Am Acad Dermatol. 2007
Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agent--St. Louis, Missouri, 2002-2006. [MMWR Morb Mortal Wkly Rep. 2007]
Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? [Nephrol Dial Transplant. 2006]
Gadolinium and nephrogenic systemic fibrosis have been the hot topic around the radiology blogosphere for last some time, here are the links—
Gadolinium related to Nephrogenic Systemic Fibrosis?
New ACR guidelines on Gadolinium in End-Stage Renal Disease
Safety warning: Nephrogenic Systemic Fibrosis (NSF)and gadolinium
Do not use Omniscan (gadodiamide) in patients with severe renal impairment (ie, GFR [glomerular filtration rate] <30ml/min/1.73m2)
Careful consideration should be given to the use of other gadolinium-containing MRI contrast agents in patients with severe renal impairment (ie, GFR <30ml/min/1.73m2).